CEO of BIC; VP of Investor Research, Life Science Nation

Lucy Parkinson is CEO of BIC and LSN’s VP of Investor Research leading LSN’s investor outreach and analysis team.  She additionally contributes to LSN’s web marketing as the voice of LSN’s videos and a contributing writer on both The Life Science Executive’s Fundraising Manifesto and the Next Phase newsletter. Prior to joining LSN, Lucy spent several years working at CPA fi­rms, gaining experience working with small corporations, partnerships and nonprofi­t organizations. Lucy graduated from the University of Leeds with a degree in the History and Philosophy of Science. She is also a FINRA-registered securities principal and an Enrolled Agent.

Consulting Scientist, BIC; CEO, NeuroLucent

Dr. Kohlbrenner is currently Chief Scientific Officer at Life Science Nation (LSN) and is Consulting Scientist for Boston Innovation Capital. In addition, he is CEO of NeuroLucent, a Chicago-based company working on Alzheimer's disease. Prior to joining LSN, Bill was a director at AbbVie, where he led a global scouting team and conducted strategic assessments of early- and late-stage pipeline opportunities. Earlier in his career, Bill led drug discovery research programs in oncology, antivirals and antibacterials. Bill has co-authored numerous research articles (~60) examining the fundamental aspects of various drug targets and the molecular basis of drug action. He received his Ph.D. from the State University of New York (SUNY) and completed postdoctoral training at the Molecular Biology Institute at UCLA.